7-[4-[[(3z)-5-Bromo-3-[4-[(5,6-dimethoxypyrimidin-4-yl)sulfamoyl]phenyl]imino-2-oxo-indolin-1-yl]methyl]piperazin-1-yl]-1-ethyl-6-fluoro-4-oxo-quinoline-3-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-[4-[[(3z)-5-Bromo-3-[4-[(5,6-dimethoxypyrimidin-4-yl)sulfamoyl]phenyl]imino-2-oxo-indolin-1-yl]methyl]piperazin-1-yl]-1-ethyl-6-fluoro-4-oxo-quinoline-3-carboxylic acid
• 英文别名: 7-[4-[[5-bromo-3-[4-[(5,6-dimethoxypyrimidin-4-yl)sulfamoyl]phenyl]imino-2-oxoindol-1-yl]methyl]piperazin-1-yl]-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
• 化学式: C₃₇H₃₄BrFN₈O₈S
• 分子量: 849.694
• InChiKey: ONLUAJYHTITDNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  56
• 可旋转键数：
  11
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  196
• 氢给体数：
  2
• 氢受体数：
  16

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 诺氟沙星 、 4-[5-Bromo-2-oxo-1,2-dihydro-indol-(3Z)-ylideneamino]-N-(5,6-dimethoxy-pyrimidin-4-yl)-benzenesulfonamide 以 水 、 溶剂黄146 为溶剂， 以66.44%的产率得到7-[4-[[(3z)-5-Bromo-3-[4-[(5,6-dimethoxypyrimidin-4-yl)sulfamoyl]phenyl]imino-2-oxo-indolin-1-yl]methyl]piperazin-1-yl]-1-ethyl-6-fluoro-4-oxo-quinoline-3-carboxylic acid
  参考文献：
  名称：

  Synthesis, antibacterial, antifungal and anti-HIV activities of norfloxacin Mannich bases

  摘要：

  Mannich bases of norfloxacin were synthesized by reacting them with formaldehyde and several isatin derivatives. Their chemical structures have been confirmed by means of their IR, H-1-NMR data and by elemental analysis. Investigation of in vitro antimicrobial activity of compounds was done by the agar dilution method against 28 pathogenic bacteria, eight pathogenic fungi and anti-HIV activity against replication of HIV-1 (III B) in MT-4 cells. The in vivo antibacterial efficacy of selected derivatives was determined using a mouse infection model. All the synthesized compounds are more active than norfloxacin against the 13 bacteria tested. The compounds are also more active than the standard drug clotrimazole against Histoplasma capsulatum. Two compounds S-8 and S-9 have shown inhibition against HIV-1 (III B) with EC50 values of 11.3 and 13.9 mu g/mL, respectively. In the mouse protection test, two compounds S-4 (ED50: 1.25 mg/kg) and S-9 (ED50: 1.62 mg/kg) are more active than norfloxacin (ED50: 6mg/kg). Among the compounds tested, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7[[N-4-[5'-bromo-3'-(4'-amino-5'-trimethoxybenzylpyrimidin-2'-yl]-imino-1'-isatinyl]methyl]N-1-piperazinyl]-3-quinoline carboxylicacid (S-9) showed promising activity in all the three tests. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(00)00125-2

文献信息

• Synthesis, antibacterial, antifungal and anti-HIV activities of norfloxacin Mannich bases
  作者：Surendra N Pandeya、Dhamrajan Sriram、Gopal Nath、Erik De Clercq

  DOI：10.1016/s0223-5234(00)00125-2

  日期：2000.2

  Mannich bases of norfloxacin were synthesized by reacting them with formaldehyde and several isatin derivatives. Their chemical structures have been confirmed by means of their IR, H-1-NMR data and by elemental analysis. Investigation of in vitro antimicrobial activity of compounds was done by the agar dilution method against 28 pathogenic bacteria, eight pathogenic fungi and anti-HIV activity against replication of HIV-1 (III B) in MT-4 cells. The in vivo antibacterial efficacy of selected derivatives was determined using a mouse infection model. All the synthesized compounds are more active than norfloxacin against the 13 bacteria tested. The compounds are also more active than the standard drug clotrimazole against Histoplasma capsulatum. Two compounds S-8 and S-9 have shown inhibition against HIV-1 (III B) with EC50 values of 11.3 and 13.9 mu g/mL, respectively. In the mouse protection test, two compounds S-4 (ED50: 1.25 mg/kg) and S-9 (ED50: 1.62 mg/kg) are more active than norfloxacin (ED50: 6mg/kg). Among the compounds tested, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7[[N-4-[5'-bromo-3'-(4'-amino-5'-trimethoxybenzylpyrimidin-2'-yl]-imino-1'-isatinyl]methyl]N-1-piperazinyl]-3-quinoline carboxylicacid (S-9) showed promising activity in all the three tests. (C) 2000 Editions scientifiques et medicales Elsevier SAS.